NCT03088930 - Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG

Crizotinib

Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.

Trial Locations (1)

80045

University of Colorado Denver, Aurora